Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results

Eriene A. Youssef, Elizabeth Berry-Kravis, Christian Czech, Randi J Hagerman, David R Hessl, Chin Y. Wong, Michael Rabbia, Dennis Deptula, Amy John, Russell Kinch, Philip Drewitt, Lothar Lindemann, Moritz Marcinowski, Rachel Langland, Carsten Horn, Paulo Fontoura, Luca Santarelli, Jorge A. Quiroz

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial, basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.

Original languageEnglish (US)
Pages (from-to)503-512
Number of pages10
JournalNeuropsychopharmacology
Volume43
Issue number3
DOIs
StatePublished - Feb 1 2018

Fingerprint

Metabotropic Glutamate 5 Receptor
Fragile X Syndrome
Adolescent Behavior
Placebos
Clinical Trials
Behavioral Symptoms
2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine
Hallucinations
Therapeutics
Knockout Mice
Psychotic Disorders
Psychiatry
Anxiety
Depression
Phenotype
Mutation

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial : FragXis Phase 2 Results. / Youssef, Eriene A.; Berry-Kravis, Elizabeth; Czech, Christian; Hagerman, Randi J; Hessl, David R; Wong, Chin Y.; Rabbia, Michael; Deptula, Dennis; John, Amy; Kinch, Russell; Drewitt, Philip; Lindemann, Lothar; Marcinowski, Moritz; Langland, Rachel; Horn, Carsten; Fontoura, Paulo; Santarelli, Luca; Quiroz, Jorge A.

In: Neuropsychopharmacology, Vol. 43, No. 3, 01.02.2018, p. 503-512.

Research output: Contribution to journalArticle

Youssef, EA, Berry-Kravis, E, Czech, C, Hagerman, RJ, Hessl, DR, Wong, CY, Rabbia, M, Deptula, D, John, A, Kinch, R, Drewitt, P, Lindemann, L, Marcinowski, M, Langland, R, Horn, C, Fontoura, P, Santarelli, L & Quiroz, JA 2018, 'Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results', Neuropsychopharmacology, vol. 43, no. 3, pp. 503-512. https://doi.org/10.1038/npp.2017.177
Youssef, Eriene A. ; Berry-Kravis, Elizabeth ; Czech, Christian ; Hagerman, Randi J ; Hessl, David R ; Wong, Chin Y. ; Rabbia, Michael ; Deptula, Dennis ; John, Amy ; Kinch, Russell ; Drewitt, Philip ; Lindemann, Lothar ; Marcinowski, Moritz ; Langland, Rachel ; Horn, Carsten ; Fontoura, Paulo ; Santarelli, Luca ; Quiroz, Jorge A. / Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial : FragXis Phase 2 Results. In: Neuropsychopharmacology. 2018 ; Vol. 43, No. 3. pp. 503-512.
@article{70a467a567c24eb196a98da022e7dfc8,
title = "Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results",
abstract = "Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial, basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.",
author = "Youssef, {Eriene A.} and Elizabeth Berry-Kravis and Christian Czech and Hagerman, {Randi J} and Hessl, {David R} and Wong, {Chin Y.} and Michael Rabbia and Dennis Deptula and Amy John and Russell Kinch and Philip Drewitt and Lothar Lindemann and Moritz Marcinowski and Rachel Langland and Carsten Horn and Paulo Fontoura and Luca Santarelli and Quiroz, {Jorge A.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1038/npp.2017.177",
language = "English (US)",
volume = "43",
pages = "503--512",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial

T2 - FragXis Phase 2 Results

AU - Youssef, Eriene A.

AU - Berry-Kravis, Elizabeth

AU - Czech, Christian

AU - Hagerman, Randi J

AU - Hessl, David R

AU - Wong, Chin Y.

AU - Rabbia, Michael

AU - Deptula, Dennis

AU - John, Amy

AU - Kinch, Russell

AU - Drewitt, Philip

AU - Lindemann, Lothar

AU - Marcinowski, Moritz

AU - Langland, Rachel

AU - Horn, Carsten

AU - Fontoura, Paulo

AU - Santarelli, Luca

AU - Quiroz, Jorge A.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial, basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.

AB - Preclinical data suggest that inhibition of the metabotropic glutamate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS). Treatment of Fmr1 knockout mice with mGluR5-negative allosteric modulators (NAMs) has been reported to correct a broad range of phenotypes related to FXS. The early short-term clinical trials with mGluR5 NAMs, including basimglurant, assessing the effects in individuals with FXS, were supportive of further exploration in larger, well-controlled trials. We evaluated basimglurant, a potent and selective mGluR5 NAM, in a 12-week, double-blind, parallel-group study of 183 adults and adolescents (aged 14-50, mean 23.4 years) with FXS. Individuals with an FMR1 full mutation were randomized to placebo or one of two doses of basimglurant. The primary efficacy endpoint was the change from baseline in behavioral symptoms using the Anxiety Depression and Mood Scale (ADAMS) total score. All treatment arms showed marked behavioral improvements from baseline to week 12 with less improvement in the basimglurant 1.5 mg arm than placebo; however, basimglurant 0.5 mg was inferior to placebo in the ADAMs total score. Treatment with basimglurant was overall well-tolerated. A higher incidence of adverse events classified as psychiatric disorders were reported in patients treated with basimglurant, including three patients with hallucinations or psychosis. In this phase 2 clinical trial, basimglurant did not demonstrate improvement over placebo. Evaluation of the overall risk-benefit in younger patient populations is an important consideration for the design of potential further investigations of efficacy with this class of medications.

UR - http://www.scopus.com/inward/record.url?scp=85040453824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040453824&partnerID=8YFLogxK

U2 - 10.1038/npp.2017.177

DO - 10.1038/npp.2017.177

M3 - Article

C2 - 28816242

AN - SCOPUS:85040453824

VL - 43

SP - 503

EP - 512

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 3

ER -